National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Ovarian Epithelial Cancer Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 07/18/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Stage I and Stage II Ovarian Epithelial Cancer






Stage III and Stage IV Ovarian Epithelial Cancer






Recurrent or Persistent Ovarian Epithelial Cancer






Get More Information From NCI






Changes to This Summary (07/18/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Cellular Classification

The following is a list of ovarian epithelial cancer histologic classifications.

  • Serous cystomas:
    • Serous benign cystadenomas.


    • Serous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).


    • Serous cystadenocarcinomas.




  • Mucinous cystomas:
    • Mucinous benign cystadenomas.


    • Mucinous cystadenomas with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low potential or borderline malignancy).


    • Mucinous cystadenocarcinomas.




  • Endometrioid tumors (similar to adenocarcinomas in the endometrium):
    • Endometrioid benign cysts.


    • Endometrioid tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy).


    • Endometrioid adenocarcinomas.




  • Clear cell (mesonephroid) tumors:
    • Benign clear cell tumors.


    • Clear cell tumors with proliferating activity of the epithelial cells and nuclear abnormalities but with no infiltrative destructive growth (low malignant potential or borderline malignancy).


    • Clear cell cystadenocarcinomas.




  • Unclassified tumors that cannot be allotted to one of the above groups.


  • No histology.


  • Other malignant tumors (malignant tumors other than those of the common epithelial types are not to be included with the categories listed above).


(Refer to the PDQ summary on Ovarian Low Malignant Potential Tumor Treatment for more information.)

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov